RE:RE:RE:RE:RE:RE:Scientists harness light therapy to target and kill cancer cCancerSlayer wrote: It appears they are also still at the preclinical stages in reference to GBM (no humans tested). But I also noted in the article that the European scientists were also very concerned about how to overcome the technical challenges of reaching deep-seated or less accessible solid tumors (like GBM) with near-infrared light. The scientists were "excited to see how this research will develop". Well, it looks like TLT may already have the advantage & answer to this technical challenge with its patented "x-ray activated" PDCs for destroying cancer.
Perhaps our in-house patent expert, Pandora, could elaborate on this...does the patent extend to all forms of radiotherapy?
I'm not good in looking at European stuff. Could not find anything in the USPTO files and the Google patent search doesn't appear to show anything other than Theralase that is less than 10 years old other than one from 2017 that was abandoned.
However I did find one in the USPTO that is interesting:
Light-activated compounds Abstract The presently-disclosed subject matter includes light-activated ruthenium compounds. In some embodiments the compounds release one or more ligands when exposed to light, and in specific embodiments the light includes a wavelength of about 500 nm to about 1000 nm. The present compounds can also comprise an overall charge, wherein the overall charge can be a positive overall charge or a negative overall charge. Further still, embodiments include methods of treating cancer in a subject by administering a compound and then exposing a site of the subject to light.
| Inventors: | Glazer; Edith C. (Lexington, KY), Heidary; David K. (Lexington, KY) |
| Applicant: | | Name | City | State | Country | Type | |
| United States Patent | 9,290,528 |
| Glazer , et al. | March 22, 2016 |